Open AccessTreatment with new oral anticoagulants in the family medicine practice
Author(s) -
Camelia Cristina Diaconu,
Bucureşti Universitatea de Medicină și Farmacie „Carol Davila“,
G. Dediu,
Mădălina Ilie,
Mihaela Adela Iancu,
Spitalul de Urgenţă Bucureşti Clinica de Medicină Clinic Internă
Publication year - 2015
Publication title -
romanian journal of medical practice
Language(s) - English
Resource type - Journals
eISSN - 2069-6108
pISSN - 1842-8258
DOI - 10.37897/rjmp.2015.4.4
Subject(s) - dabigatran , apixaban , rivaroxaban , medicine , intensive care medicine , edoxaban , anticoagulant , drug , concomitant , clinical practice , vitamin k , oral anticoagulant , warfarin , pharmacology , atrial fibrillation , surgery , physical therapy
Vitamin K antagonists represented for more than 50 years the only oral anticoagulant treatment option, though encumbered by numerous food and drug interactions, with direct impact on the safety and efficacy of this treatment. The frequent complications of anticoagulant treatment with vitamin K antagonists led to the need for the emergence of new oral anticoagulants (NOAC). The main NOACs used today are dabigatran, rivaroxaban and apixaban. NOAC have a number of advantages over antivitamin K anticoagulants: fewer drug interactions, no food interactions, rapid onset of the anticoagulant action, rapid clearance, no need for INR monitoring. NOAC therapy must be individualized according to patient age, comorbidities and medical history, renal function, concomitant medications. Given that clinical experience with NOAC is still limited in practice, physicians (including family physicians) must monitor these patients and need to pay attention and report any side effects.